NeoStem to Present at Two Industry Conferences This Week

NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that Dr. Robin Smith, the Company's Chairman and CEO, will present at the NYC MedTech Conference being held at the New York Merrill Lynch offices on Wednesday, August 11, 2010 and at the WallStreet Research VI Small Cap Research Conference on Thursday, August 12, 2010.

"Having been awarded a $700,000 contract from the U.S. Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research Center (USAMRMC-TATRC), closed on a $5,000,000  round of financing and signed an exclusive contract with the Vatican's Pontifical Council for Culture who has undertaken to commit $1,000,000 to start the collaboration and being awarded 'The Best Stem Cell Company' for 2010 by The New Economy's Biotech Awards, we are excited to share our story with the investor community," said Dr. Robin Smith.

The WallStreet Research VI Small Cap Conference will be held on August 11-12, 2010 at the Penn Club of New York in New York. Dr. Smith is scheduled to make a presentation at 10:40 a.m. ET on Thursday, August 12, 2010, and will be available to meet with investors throughout the conference.  The conference will be available on webcast for live viewing at http://www.visualwebcaster.com/event.asp?id=71320. The NYC MedTech Conference Event will be held on August 11, 2010 at 5:30 p.m. at The Merrill Lynch Offices in the Met Life building (200 Park Avenue).  Dr. Smith is scheduled to present at 6:50 p.m. ET.

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL™ Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties.  The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K  filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

About WallStreet Research Small Cap Conference

WallStreet Research, an affiliate of Alan Stone & Company LLC, is proud to sponsor the sixth annual WallStreet Research Small Cap Conference, hosted again by Alan Stone. These networking and investment events bring together some of the top emerging companies from America and abroad. WallStreet Research serves as an information link between emerging growth public companies and investors in the financial marketplace and provides the investment community with independent research coverage of selected quality small cap stocks.

About NYC MedTech

This forum, held six times a year, allows companies to present their science and technology in an environment consisting of industry, academia, researchers and talented individuals as well as investment professionals. In addition the audience also hears unique, timely and relevant information from the guest speaker presentation. The forum is hosted by, John R. Lieberman CPA/PFS at Perelson Weiner, LLP, Wendy Brown of Merrill Lynch and Ted King of SaddleRock Advisors.

SOURCE NeoStem, Inc.